Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

Inclusion Criteria: * Randomized and completed 12-months of participation in the Hope Study (CA-0011) * Non-childbearing potential or using adequate birth control * Available/consenting Study Partner Exclusion Criteria: * Insufficient adherence to treatment in the Hope Study (CA-0011) * Living in continuous care nursing home (assisted living permitted) * Initiating or ongoing treatment with any of the following during study participation: * Immunomodulators or passive immunotherapies for AD (ie, monoclonal antibodies) * Memantine (Namenda or Namzaric) * Nootropic drugs except stable acetylcholinesterase inhibitors For more information about the Hope Study (CA-0011) that participants in this study complete first, please see: https://www.hopestudyforad.com/ or the Hope Study ClinicalTrials.gov posting here: https://clinicaltrials.gov/study/NCT05637801